What is the primary change regarding executive severance at AbbVie?

AbbVie has implemented a new Severance Agreement Policy that caps cash severance for executive officers at 2.99 times the sum of their base salary and non-equity incentive plan bonus. Any severance exceeding this limit will require ratification by a majority of stockholder votes.

What are the key terms of the new Change in Control (CIC) agreements for executives?

The new CIC agreements, effective January 1, 2023, will provide Named Executive Officers (NEOs) with a lump sum payment equal to 2.99 times their annual base salary and bonus if they are terminated without cause or permanent disability, or if they resign for Good Reason, within two years following a change in control.

How will the By-laws amendments affect stockholder meetings and director nominations?

The amended By-laws clarify procedures for director nominations and stockholder proposals, notably requiring nominees to demonstrate compliance with universal proxy rules. They also formally allow for stockholder meetings to be conducted via remote communication, offering greater flexibility in meeting formats.

Are these changes related to any specific regulatory requirements?

The amendments, particularly regarding universal proxy rules and executive compensation limits, are likely in response to evolving corporate governance best practices and regulatory considerations aimed at increasing transparency and accountability to shareholders.

ABBV 8-K: Leadership Changes & Corporate Changes

Summary

AbbVie Inc. (ABBV) filed an 8-K on October 13, 2022, detailing significant updates to its executive compensation policies and corporate governance regarding stockholder meetings. The company's Board of Directors adopted a new Severance Agreement Policy that limits cash severance for executive officers to 2.99 times base salary plus non-equity incentive plan bonus, requiring stockholder ratification for any excess. This policy aligns with updated Change in Control (CIC) agreements to be entered into with Named Executive Officers (NEOs) effective January 1, 2023. The CIC agreements also stipulate a 2.99 times base salary and bonus payout upon termination without cause or for good reason within two years of a change in control. Additionally, AbbVie amended its By-laws to refine director nomination and stockholder proposal procedures, including explicit compliance requirements with universal proxy rules, and to formalize the ability to conduct meetings via remote communication. These changes aim to enhance corporate governance and clarify executive compensation and operational procedures.

Key Highlights

1AbbVie adopted a new Severance Agreement Policy limiting cash severance for executives to 2.99 times base salary plus bonus, subject to stockholder ratification for amounts exceeding this.
2New Change in Control (CIC) agreements for Named Executive Officers (NEOs) will provide a lump sum payment of 2.99 times annual base salary and bonus upon termination without cause or for good reason within two years of a change in control.
3These CIC agreements are set to be entered into by January 1, 2023, and will have an initial term through December 31, 2027, with renewal options.
4The company's By-laws were amended and restated to enhance director nomination and stockholder proposal procedures.
5A key amendment requires stockholders nominating directors to provide evidence of compliance with universal proxy rules (Rule 14a-19).
6The By-laws now formally permit stockholder meetings to be held by remote communication.
7The Board of Directors retains the ability to set procedures for conducting stockholder meetings.

AbbVie Inc. 8-K Report, Executive Changes (Oct 14, 2022)

Summary

Key Highlights

Frequently Asked Questions